What Ichnos Sciences does

Ichnos Glenmark Innovation (IGI, Inc.), operating under the Ichnos Sciences brand, is a private clinical-stage biotechnology company developing innovative biologics for oncology. The company is a joint venture combining Glenmark's pharmaceutical infrastructure with Ichnos's biologics discovery capabilities, and is headquartered in New York with additional operations in Switzerland (process development, manufacturing, and a research center at Biopole, Lausanne) and India (R&D support hub in Mahape, Mumbai). IGI focuses on hematological malignancies and solid tumors, with stated patients as the end-user beneficiary.

The company's core technology is the proprietary BEAT® protein engineering platform, which enables development of full-length multispecific antibodies with an emphasis on flexibility and manufacturability. Its lead clinical asset is ISB 2001, a first-in-class trispecific antibody (CD38 x BCMA x CD3) in Phase 1b development for multiple myeloma, designed to overcome mechanisms of escape from existing treatments. The pipeline additionally includes ISB 2301, a preclinical next-generation multispecific immune cell activator that targets three tumor-associated antigens and engages both T cells and natural killer (NK) cells, plus earlier-stage candidates ISB 1442, ISB 1342, and GRC 54276. IGI employs approximately 100 people across its three innovation centers, with a management team reporting 120+ years of combined pharmaceutical and biotech experience and a Scientific Advisory Board with expertise in immuno-oncology and protein engineering.

As a clinical-stage company, IGI's revenue model is predicated on advancing pipeline candidates through clinical development toward regulatory approval, with future economics expected to flow from licensing, royalties, or partnership-based commercialization rather than current product sales. The company distributes information through its corporate website, scientific publications, medical conference presentations, and a LinkedIn presence, and has signaled openness to external collaboration through a dedicated partnerships channel. No funding rounds, revenue figures, or public institutional investors are disclosed in the source data.

Name

Ichnos Sciences

Legal name

IGI, Inc.

Website

https://ichnossciences.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

251–500 employees

Short description

Ichnos Glenmark Innovation (IGI, Inc.) is a private clinical-stage biotechnology company developing first-in-class multispecific antibody therapies in oncology, powered by its proprietary BEAT® protein engineering platform, with a lead asset (ISB 2001) in Phase 1b for multiple myeloma and a preclinical solid-tumor candidate (ISB 2301).

Ownership category

akta.pro rank

Product category

Oncology Biologics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)

akta.pro secondary industry

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

Keywords

• Oncology biologics
• Multispecific antibodies
• Cancer therapeutics
• Biopharmaceutical research
• Clinical-stage biotechnology

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Others

Revenue model

1. Pipeline Development and Potential Commercialization: As a clinical-stage biotechnology company, IGI is developing novel biologics in oncology. The revenue model is based on advancing pipeline candidates through clinical development toward potential regulatory approval and commercialization, with focus on hematological malignancies and solid tumors.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Ichnos Sciences is a clinical-stage biotechnology company that develops innovative multispecific antibody therapeutics for the treatment of cancer. The company leverages its proprietary BEAT® technology platform to engineer biologics that engage multiple immune system targets, with a current pipeline of candidates targeting hematological malignancies and solid tumors at preclinical to Phase 1b stages of development.

Product overview

IGI, Inc. (Ichnos Glenmark Innovation) is a global, clinical-stage biotechnology company developing innovative biologics in oncology. The company operates with its proprietary BEAT® technology platform for developing multispecific antibodies. The core pipeline includes ISB 2001 (CD38 x BCMA x CD3 trispecific T cell engager in Phase 1b for multiple myeloma) and ISB 2301 (next-generation multispecific immune cell activator in preclinical stage targeting 3 tumor-associated antigens and activating both T cells and NK cells). Additional pipeline candidates include ISB 1442, ISB 1342, and GRC 54276. The company's Multispecifics™ portfolio targets hematological malignancies and solid tumors, aiming to deliver breakthrough curative therapies.

Differentiator

Problem solved

Functional benefit

Products and services

• ISB 2001

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• GlenmarkcoreStrategic or Co-development PartnerIchnos Glenmark Innovation (IGI) is a joint venture/partnership between Ichnos and Glenmark, combining Glenmark's legacy and Ichnos's innovative biologics capabilities to develop breakthrough oncology therapies. The partnership leverages Glenmark's pharmaceutical expertise and infrastructure alongside Ichnos's proprietary BEAT® technology platform.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Zymeworks: Zymeworks develops multispecific antibodies using its Azymetric and EFECT platforms for oncology indications, making it a direct competitor to IGI's BEAT® multispecific antibody platform. Both companies focus on engineering novel antibody formats to engage multiple targets simultaneously in cancer treatment.
• Genmab: Genmab is a leading developer of bispecific antibodies using its proprietary DuoBody platform, with approved products including teclistamab for multiple myeloma — directly competing with IGI's ISB 2001 in the same indication. Both companies engineer multispecific antibodies for hematologic and solid tumor oncology.
• MacroGenics: MacroGenics develops multispecific antibodies (DART and TRIDENT platforms) for cancer immunotherapy, with multiple clinical-stage oncology assets. Their T cell engager approach and protein engineering platform closely parallel IGI's BEAT® technology and multispecific strategy.
• Xencor: Xencor's XmAb protein engineering platform generates bispecific and multispecific antibodies with multiple clinical-stage oncology assets. Like IGI, Xencor focuses on engineering novel antibody formats to address oncology indications including hematologic malignancies.
• Harpoon Therapeutics (acquired by Merck): Harpoon developed T cell engagers using its TriTAC and ProTriTAC platforms for multiple myeloma and solid tumors, with HPB-2001 (BCMA x CD3 x albumin) being a near-direct competitor to IGI's ISB 2001. Acquired by Merck in 2024, validating the strategic value of the T cell engager space IGI plays in.
• Maverick Therapeutics (acquired by Takeda): Maverick developed conditional T cell engagers (COBRA platform) for solid tumors, with a similar multispecific approach to IGI's pipeline. Acquired by Takeda in 2021, representing another validation of the multispecific T cell engager space IGI operates in.

Broad incumbents

• Regeneron: Regeneron is a major biopharmaceutical company with bispecific antibody capabilities (linvoseltamab for multiple myeloma, odronextamab) and a broader oncology and antibody portfolio. As a broad incumbent, it competes with IGI's multispecific approach while also offering partnership/licensing optionality.
• Roche: Roche has extensive bispecific antibody capabilities through its CrossMAb and other platforms, with approved products like glofitamab and mosunetuzumab. As a broad incumbent with deep oncology infrastructure, Roche is both a potential competitor and a likely partnership/licensing partner for clinical-stage multispecific antibody developers like IGI.

Emerging players

• AbCellera Biologics: AbCellera operates an antibody discovery and engineering platform partnering with multiple biotech and pharma companies to develop therapeutic antibodies. While not directly developing multispecific assets like IGI, it represents an alternative platform-based antibody discovery model in the same therapeutic space.
• CytomX Therapeutics: CytomX develops Probody therapeutics — conditionally activated antibodies designed to improve tumor selectivity. Their platform-based approach to engineering antibody specificity in oncology parallels IGI's BEAT® platform strategy of using protein engineering to overcome therapeutic limitations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/ichnos-glenmark-innovation

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ichnos Sciences